Alumis (ALMS) announced data from a Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics, PK, of single- and multiple-ascending doses of A-005, a potent, selective, central nervous system, CNS, penetrant TYK2 inhibitor, in healthy participants. In the clinical trial, A-005 was well tolerated with no serious adverse events reported. A-005 demonstrated the ability to penetrate into the CNS with significant and prolonged exposure in the cerebral spinal fluid. A-005 levels in the CSF were comparable to or exceeded the free drug exposure in plasma and exceeded IC90 levels in cell-based assays.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALMS:
- Alumis Inc. Reports Q3 2024 Financial Results and Advances Clinical Programs
- Alumis price target lowered to $26 from $30 at H.C. Wainwright
- Alumis initiated with an Outperform at Baird
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
